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Abstract 
Background: Endometrial hyperplasia is a major concern for women that start estrogen replacement therapy (ERT) to control 
symptoms experienced during perimenopause and postmenopause.  Progesterone provides protection against endometrial 
hyperplasia, and there are multiple dosage forms of progesterone available.  Intrauterine progesterone may offer an appealing option 
with additional benefits beyond endometrial protection for patients. 
Objective: The overarching objective of this systematic review is to characterize the relationship between levonorgestrel containing 
intrauterine devices (LNG-IUD) and the prevention of endometrial hyperplasia in peri- and postmenopausal women. Specifically, this 
systematic review addresses whether LNG-IUD has equivalent efficacy of protecting against endometrial hyperplasia, but an improved 
safety profile when compared to oral progesterone in women using ERT. 
Methods: OVID Medline, Scopus, and Cochrane were used to find available studies that have investigated the relationship between 
endometrial hyperplasia prevention and varying dosage forms of progesterone. Randomized control studies comparing LNG-IUD with 
no treatment, placebo, or other hormonal therapy in adult females were included. In addition, due to a lack of randomized control 
studies, four non-comparative studies were included.  
Results: There were eleven total studies included that investigated LNG-IUD use in women on ERT. According to the studies, the LNG-
IUD was equally effective as other routes (oral, vaginal) of progesterone administration in protecting against endometrial hyperplasia.  
Conclusions: The LNG-IUD prevents endometrial proliferation at least as effective as oral or vaginal forms of progesterone. LNG-IUD is 
a safe option for women starting estrogen replacement therapy and has added benefits due to decreased adverse effects.  
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Introduction 
According to the American Cancer Society, cancer of the 
endometrium has the highest incidence of the female 
reproductive organs in the United States.1 A risk factor of 
endometrial cancer is endometrial hyperplasia, which is caused 
by excess proliferation of the endometrium. Unopposed 
endometrial exposure to estrogen can lead to endometrial 
hyperplasia or cancer of the endometrium for perimenopausal 
and postmenopausal women. Estrogen hormone therapy is the 
most effective treatment for vasomotor symptoms and 
genitourinary syndrome (GSM), which many women 
experience during the menopause transition and into the 
postmenopausal state.  
 
To protect against the proliferation of the endometrium and 
decrease the risk of developing endometrial hyperplasia or 
endometrial cancer, progesterone must be added to the 
estrogen therapy. Traditionally, oral, transdermal, or vaginal 
progesterone products have been prescribed to protect the 
endometrial integrity from the effects of systemic estrogen 
therapy, but these dosage forms are associated with adverse  
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side effects.2 The North American Menopause Society (NAMS) 
addresses that non-oral routes of administration, such as 
intrauterine systems, may offer potential advantages due to 
bypassing the first-pass hepatic effects and a reduction of side 
effects caused by systemic progesterone products.2 
Levonorgestrel Intrauterine Device (LNG-IUD) provides 
additional benefits including contraception for women in 
perimenopause, increases compliance, effectively manages 
bleeding problems during the transition from peri-menopause 
to postmenopause, and may increase quality of life.  There is 
some evidence that the addition of progesterone containing 
LNG-IUD to estrogen hormone therapy has equal efficacy in 
preventing endometrial hyperplasia, by conversion of the 
anovulatory endometrium into an atrophic endometrium with 
infrequent, light bleeding.3 More importantly, the use of LNG-
IUD for women on estrogen therapy may decrease toxicities 
and medication burden. In addition to providing contraception 
for perimenopausal women and managing bleeding events, 
there are other benefits of LNG-IUD over systemic exposure. 
Common adverse effects of systemic progesterone therapy are 
breast tenderness, edema, mood changes, and weight gain. 
However, with LNG-IUD a lower dose is used due to direct 
exposure in the uterus;  systemic exposure is therefore 
minimized  and the common side effects associated with 
progesterone are reduced.4 
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Methods 
The methods section followed the Preferred Reporting Items 
for Systematic Review and Meta-Analyses (PRISMA) checklist as 
closely as possible.5 The Patient, Intervention, Control, and 
Outcome parameters (PICO) of this systematic review were as 
follows: The patient population included are perimenopausal 
and postmenopausal women on estrogen replacement therapy 
with an intact uterus. The intervention was levonorgestrel 
intrauterine device. The comparison or control was patients on 
either oral, transdermal, or vaginal forms of progesterone 
therapy, which are the current standard of care. The exception 
to this were four non-comparative studies. The outcomes 
included were endometrial hyperplasia incidence, excessive 
uterine bleed events and incidence of adverse drug reactions. 
In addition, the number of participants that were excluded from 
the study was reported. These outcomes were specifically 
chosen because each one evaluates the efficacy of the 
levonorgestrel intrauterine device being an equivalent 
substitute for oral, transdermal, or vaginal progesterone 
products for preventing endometrial hyperplasia in women 
using estrogen replacement therapy, while also determining 
the safety profiles of different routes of administration.  
 
The inclusion criteria were randomized control studies 
comparing LNG-IUD with no treatment, placebo, or other 
hormonal therapy in adult females, case control studies, and 
non-comparative studies in English. The design of the review 
was broad due to the limitation of data available.  Any patient 
population that was in perimenopause or postmenopause was 
included, unless one of the exclusion criteria fit. The exclusion 
criteria were expert opinion publications and review articles, 
and studies that examined women already diagnosed with 
endometrial hyperplasia, endometrial cancer, or any other 
disease of the uterus.  Subjective based studies were included 
to evaluate the safety profile of LNG-IUD use.  Some of the side 
effects evaluated were less measurable and data was based on 
the patients’ qualitative responses (i.e. vasomotor symptom 
relief).  
 
The search engines utilized were Ovid Medline, Cochrane,  
and Scopus. The basic search terms included were 
levonorgestrel, intrauterine devices, endometrium and 
endometrial hyperplasia. The search of Ovid Medline was 
between January 1st 1960 - April 16th, 2018. The search was 
limited to 1960 or later, because the use of estrogen 
replacement therapy nearly doubled between 1960 and 1975.6 
Cochrane and Scopus were searched with similar key terms. 
Another strategy for finding studies and additional information 
was by looking through the references of studies that were 
identified and included in this review. Please see Appendix A for 
a detailed outline of the Ovid Medline, Cochrane, and Scopus 
search strategies used. A librarian at the University of 
Minnesota Biomedical Library was consulted to suggest 
appropriate search engines to use for the research question 
and to validate the search algorithm carried out. 
 
Study selection and data extraction 
After identifying an initial list of studies based on the search 
criteria, it was further narrowed down by the inclusion and 
exclusion criteria listed above. The studies that were not 
rejected based on the abstract and title were read in full to 
determine eligibility based on the inclusion and exclusion 
criteria by one author (KC). While analyzing each paper the 
references of some articles were used to find additional studies 
that potentially fit the criteria of the systematic review. Key 
components from the studies were chosen and synthesized 
(see Table 1).  
 
Quality of evidence and risk of bias in individual studies  
The articles were methodologically appraised using the 
checklist on the Critical Appraisal Skills Programme (CASP) 
criteria to determine quality and risk of bias7 (see Table 2). In 
the end, the articles were categorized as “high”, “moderate” or 
“low” according to the analysis of each study (see Table 2). The 
Cochrane risk of bias tool was used to evaluate the bias of each 
study8 (see Table 3). There were four studies included that were 
not randomized controlled studies, but rather non-comparative 
prospective study so there was inherent bias within those 
studies.   
 
Results  
From the three search engines used, 160 potential studies were 
identified using the search terms described above, but 13 were 
removed as duplicates. The titles and abstracts were reviewed 
and 124 studies were removed as a result of not meeting the 
inclusion/exclusion criteria outlined (see Figure 1). The full text 
of the remaining 23 studies were assessed.  Figure 1 includes 
the rationale for exclusion of 12 articles. References of the 
studies found were also investigated for more eligible studies, 
but none were identified. After going through this process, 
eleven studies were included in this systematic review.  
 
The eleven studies identified for inclusion were completed 
within the last 30 years, which has been a time of increased 
research on perimenopausal and postmenopausal hormone 
therapy. A majority of the studies selected were randomized 
control trials, but there were four of the eleven that were non-
comparative prospective studies. There is limited data 
available, so it was determined to be appropriate to include 
these additional studies. A summary of the characteristics and 
key findings of the eleven studies can be found in Table 1.  
 
All seven of the randomized control studies selected had a low 
risk of bias based on the Cochrane Risk of Bias tool.  Using the 
CASP checklist, the quality of the evidence was high and there 
was a low risk of bias. As expected, the 4 non-comparative 
studies had a high risk of bias using both tools (see Tables 2 and 
3). 
 
A study by Andersson et al. published in 1992 compared 20-mcg 
levonorgestrel-IUD continuous and 2 mg oral estradiol valerate 
daily versus a 28-day cycle of 2 mg oral estradiol valerate daily 
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for days 1-21 and 250 mcg oral levonorgestrel on days 11-21.9 
The 40 perimenopausal women enrolled in the study were 
followed for 1 year, with 3 participants withdrawing from the 
study. There were 2 women that were excluded due to adverse 
effects. The main outcomes reported were endometrial 
histopathology and bleeding patterns. After 12 months, no 
endometrial hyperplasia was reported in either treatment 
group. The group in the cyclic treatment continued to have 
bleeding/spotting for an average of 6 days, whereas the LNG-
IUD group had 83% of women become amenorrhoeic after the 
12-month study.9  
 
A study by Raudaskoski et al. published in 1995 compared 
continuous 20-mcg levonorgestrel-IUD and 50-mcg 
transdermal estradiol versus continuous 1 mg oral 
norethisterone acetate daily and 2 mg oral estradiol valerate 
daily.10 The 40 postmenopausal women enrolled in the study 
were followed for 1 year, except eight participants that 
withdrew from the study. Of the eight participants, five 
withdrew from the LNG-IUD and three withdrew from the 
comparative group. The main outcomes reported were 
endometrial histopathology and bleeding patterns. They found 
no endometrial hyperplasia in either group after 12 months. 
After 12 months of treatment there was no difference in the 
bleeding pattern between the groups. There were less 
progesterone related side effects (headache, breast 
tenderness, etc.) reported in the LNG-IUD group compared to 
the other treatment group.10  
 
A study done by Antoniou et al. published in 1997 compared 
20-mcg levonorgestrel-IUD and 50-mcg estradiol transdermal 
patch continuously versus 2 mg estradiol vaginal ring 
continuously and 100 mg vaginal progesterone suppository 
daily for 7 days every month.11 The 56 postmenopausal women 
were followed for 1 year. The major outcomes followed were 
endometrial thickness and reported bleeding/spotting by study 
subjects. There was no evidence of endometrial proliferation in 
either group. The LNG-IUD group had more bleeding days than 
the comparative group during the first months of treatment, 
but by the end the differences were no longer seen.11  
 
A study done by Suvanto-Luukkonen et al. compared 20-mcg 
LNG-IUD in combination with 1.5 mg transdermal estradiol gel 
(150 mcg/day) versus 1.5 mg transdermal estradiol gel (150 
mcg/day) with 100 mg oral natural micronized progesterone 
capsules daily OR 100 vaginal progesterone on days 1-25 per 
month.12 There were 12 women in the vaginal progesterone 
group that had progesterone increased to 200 mg due to 
abnormal bleeding. The 51 postmenopausal women were 
followed for 1 year. The major outcome investigated in the 
study was endometrial responses based on endometrial biopsy. 
The results showed that LNG-IUD protected the endometrium 
from proliferation, whereas the dose chosen for the oral and 
vaginal form of natural progesterone was not sufficient and 
proliferative features were seen in approximately half of the 
endometrial specimens.12  
A randomized control study done by Wollter-Svensson et al. 
investigated the histopathology of the endometrium and 
bleeding patterns while using different strengths of LNG-IUD (5-
mcg or 10-mcg).13 The study was done at two health centers- 
one center started all women (n=51) on 50 mcg/24 hours 
transdermal estradiol and the other center had women (n=57) 
start on 2 mg oral estradiol. Then the women were randomized 
to receive either the 5-mcg or the 10-mcg LNG-IUD. There were 
12 women, 6 from each IUD group, that withdrew from the 
study; 7 of the women that discontinued was a result of 
bleeding pattern. One women in the study did have a 
proliferative endometrium after 1 year, but the likely 
explanation for this is her first IUD was replaced due to 
expulsion. After 12 months of  LNG-IUD insertion, 59 out of 96 
women (65%) reported amenorrhea.13 
 
A prospective study done by Raudaskoski et al. published in 
2002 compared 20-mcg levonorgestrel-IUD and 2 mg estradiol 
oral daily versus 2 mg estradiol oral daily and 
medroxyprogesterone acetate 5 mg on 14 out of 30 days.14 
There were a total of 109 postmenopausal, European women 
that were followed for 1 year. The main outcomes investigated 
were histopathology of the endometrium and bleeding 
patterns. After 6 months of using the LNG-IUD, 54 out of the 55 
women had no bleeding. In contrast, the comparative group 
continued to have predictable bleeding during the withdrawal 
time from progesterone. After the completion of the study it 
was found that all women in the LNG-IUD group had 
endometrial suppression and no proliferation, whereas the 
comparative group (medroxyprogesterone) found 18 out of 47 
women with proliferation of the endometrium. Therefore, the 
medroxyprogesterone and estradiol combination did not fully 
suppress the endometrium.14  
 
A study done by Boon et al. compared 20-mcg levonorgestrel-
IUD combined with 2 mg oral estradiol daily versus the cyclic 
oral norethisterone 1 mg administered on days 1-22 and oral 
estradiol 2 mg on days 1-21, then 1 mg on days 22-28 of a 28 
day cycle.15 The main outcomes investigated were endometrial 
protection and bleeding patterns. No endometrial hyperplasia 
was found in either group. In this study there were 8 total 
reference periods, with a reference period defined by 3 of the 
28-day cycles. After the 8th reference period it was found that 
62% of the women in the LNG-IUD group were amenorrhoeic. 
Whereas, the majority of the comparative cyclic group 
continued to have normal bleeding patterns.15  
 
A non-comparative study done by Wildemeersch et al. 
published in 2005 investigated the effectiveness of 14 -mcg 
levonorgestrel IUD and 1.5 mg oral estradiol in perimenopausal 
and postmenopausal women.16 The main outcomes 
investigated were endometrial safety and patient acceptance. 
There was a total of 150 women that participated, 94 were 
perimenopausal and 56 were postmenopausal. There was a 
total of 8 women that withdrew from the study, and reasons 
varied from non-compliance, abnormal bleeding and pain 
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complaints. No proliferation was found and inactive 
endometrium was dominant.16  
 
A second non-comparative study done by Wildemeersch et al. 
published in 2007 investigated the effectiveness of 20-mcg 
LNG-IUD in combination with 1.5 mg oral estradiol daily 
continuously in suppressing the endometrium from 
proliferation.17 The 102 postmenopausal women were followed 
for a total of 5 years to determine the endometrial safety of 
LNG-IUD. The main outcome of the study was endometrial 
histology. A biopsy and examination of the endometrium was 
conducted after 3 years (at which time the LNG-IUD was 
removed and replaced) and again at the conclusion of the 
study. There were also follow ups with endometrial ultrasound 
at months 1, 3, 6 and 12 months following the insertion of the 
IUD and then at 6-month intervals during the 5-year period. A 
thin endometrium was maintained by all women throughout 
the entire study. There were two women with weak 
endometrial proliferative activity, but there were no women 
with endometrial hyperplasia17.  
 
In a similar design, another 5-year non-comparative 
prospective study was done by Hampton et al. in 2005, looking 
at 82 perimenopausal women that received oral conjugated 
equine estrogen (CEE) 1.25 mg daily and 20-mcg LNG-IUD.18 The 
objective was to determine the long-term efficacy of using LNG-
IUD to protect the endometrium from hyperplasia. Each year 
endometrial biopsy and histological assessment was 
conducted.  There were 8 women that withdrew due to adverse 
effects, 1 woman withdrew due to partial expulsion of the IUD, 
and 7 women discontinued for reasons unrelated to the 
treatment. The other 5 discontinuations were women that 
completed the study at 24 months but did not wish to continue 
with the extension of the study. No endometrial hyperplasia 
was found at the end of the 60-month study. Vasomotor 
symptoms (hot flushes, sweating, and vaginal discomfort) all 
improved significantly during the first 2 years of treatment. For 
instance, 35.4% of women at the study entry reported no hot 
flushes and after 6 months, 84.4% reported no hot flashes. In 
addition, vaginal bleeding was reported through the study 
participants recording in a ‘bleeding diary’. Amenorrhea was 
reported in 54.3% of women during reference period 6a and 
85.4% during the final reference period. 18 
 
A follow-up study done by Varila et al. studied the effects of 
replacing the LNG-IUD after 5 years of use when used for ERT 
and how endometrial histology is affected.19 Initially, there 
were 40 women enrolled in the 12-month study that started 
ERT with 20-mcg LNG-IUD and either 50 mcg transdermal or 2 
mg oral estradiol; 39 women finished the 12 months of 
treatment. All participants that finished the 12 months had no 
evidence of endometrial hyperplasia and 25 (64%) women were 
amenorrheic. The women were permitted to continue ERT with 
the LNG-IUD and estrogen of choice for 5 years. After 5 years 
had passed there were 32 women still using LNG-IUD and 29 of 
the women consented to participate in the follow-up study 
where the LNG-IUD would be replaced with a new one. Of the 
29 women, there was no evidence of endometrial hyperplasia 
after 5 years of LNG-IUD treatment. At 3 months post re-
insertion of the new LNG-IUD, 5 women were amenorrheic and 
the median number of spotting days was 3.19 
 
Discussion 
All seven of the RCT’s demonstrated that none of the 
participants in the LNG-IUD group developed endometrial 
hyperplasia while on ERT.9-15 Furthermore, the four non-
comparative studies had a combined total of 351 women (154 
perimenopausal and 197 postmenopausal) that did not have 
endometrial proliferation.16-19 This suggests that the LNG-IUD 
has no additional safety risks in regard to endometrium 
protection, when comparing to other dosage forms of 
progesterone (oral and vaginal).  Although the risk of bias is 
higher with the inclusion of the four non-comparative trials16-19, 
the endometrial safety results are consistent across all of the 
studies reviewed.9-19  
 
It is important to compare the medications and strengths used 
in the studies to the current commercially available hormone 
preparations in the United States to gauge the quality and 
relevance of the studies investigated.  Some examples of 
products available are: conjugated estrogens, estradiol, 
medroxyprogesterone acetate, and micronized progesterone.2 
In addition, there are multiple ways to dose hormone therapy, 
including continuous or cyclic, and via multiple routes of 
administration, including oral, transdermal, or vaginal.  When 
comparing the commercially available products to the selected 
studies, the dosing regimens appear appropriate and similar to 
current clinical practice, with the exception that vaginal 
progesterone for endometrial protection is not widely used in 
clinical practice.  For the study which used natural progesterone 
compared to LNG-IUD, the LNG-IUD group was successful in 
suppressing proliferation of the endometrium, but the 
comparative group that received either 100 mg or 200 mg of 
natural progesterone (oral or vaginal) had a clinically significant 
number of women that had endometrial proliferation.  Since 
the estrogen used in this study was an estradiol gel 1.5 mcg 
daily, it is unclear if the dose of estrogen was too high or if the 
progesterone dose or route was inadequate to provide 
protection.12  
 
Additionally, if we look at the bleeding patterns that were 
monitored in multiple studies we can compare differences in 
the dosage forms. Two of the studies found that there were 
similar bleeding events between the two treatment groups 
after 12 months of treatment. Although in both of the studies, 
there was more frequent spotting during the first three months 
of treatment with the LNG-IUD.10,11 Three of the randomized 
control studies saw less bleeding in the LNG-IUD group than the 
comparative group, though this was likely due to the cyclic 
progesterone used in the comparative groups which led to 
predictable withdrawal bleeding.9,14,15 One study found after six 
months of treatment that 98.2% of postmenopausal women 
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had no bleeding in the LNG-IUD group, whereas all 
postmenopausal women in the cyclical medroxyprogesterone 
group had withdrawal bleeding.14 This suggests that LNG-IUD as 
a progesterone dosage form when concomitantly used with 
estrogen replacement therapy may be a superior option for 
women that would prefer no bleeding or spotting while on 
treatment, though continuous dosing of oral progesterone may 
achieve similar outcomes of no bleeding.  Another important 
point to consider is the strength of levonorgestrel used in the 
treatment. The study that investigated use of 5-mcg and 10-
mcg LNG-IUD, instead of the higher strength (20-mcg), found 
the proportion of women with bleeding/spotting during the 
first three months of therapy is slightly higher and the 
proportion of women with amenorrhea at 1 year is lower when 
compared to studies utilizing 20-mcg LNG-IUD.13 It is therefore 
possible that the higher dose of LNG may be more favorable in 
respect to bleeding patterns.  
 
The last outcome addressed in the PICO was the frequency of 
adverse side effects associated with progesterone therapy. As 
a result of this data being subjective, it was more difficult to 
determine if one treatment group was superior to the other in 
regard to adverse side effects. All of the selected studies found 
a reduction in the vasomotor symptoms,9-17, but not all 
investigated the frequency of progesterone related side effects 
in the results. In one of the non-comparative studies there were 
no side effects (breast tenderness, headaches, bloating, etc.) 
related to LNG-IUD reported.16 In another study no women in 
the LNG-IUD group complained of symptoms related to 
progesterone delivery, but one participant receiving oral 
progesterone withdrew due to headaches and two others in 
this group reported breast tenderness.10  Whereas, in another 
study one woman receiving LNG-IUD discontinued due to 
headaches and breast tenderness.18 
 
One of the benefits of LNG-IUD is contraception during 
perimenopause. Four of the studies chosen included 
perimenopausal women and there were no exclusions for 
pregnancy.9,15,16,18 One study stated, that although not designed 
to evaluate contraception efficacy, many of the women relied 
on the IUD for contraception; during the 318 woman years of 
exposure no conceptions occurred to the study treatment.18 
This suggests that the LNG-IUD successfully provided 
contraception for women transitioning from perimenopause to 
menopause, while decreasing bothersome vasomotor 
symptoms through safe use of ERT. 
 
Limitations 
A thorough search was done by using the above strategy 
outlined in the methods, but it is possible bias may exist due to 
the chance that some data was unpublished or not uncovered 
based on the terms used. One weakness of all the studies 
investigated is the difficulty in blinding participants to use of 
LNG-IUD, because inserting the LNG-IUD is a procedure that 
would not be possible to blind. In addition, it would be hard to 
blind the reviewers and clinicians for the same reason. 
Furthermore, there may be some scrutiny based on the 
publication date of the studies evaluated.  
 
The use of LNG-IUD has proven to provide equivalent 
protection of the endometrium when estrogen replacement 
therapy is used during perimenopause and postmenopause for 
women. The studies examined show similar findings of 
available research on the use of LNG-IUD in preventing 
endometrial hyperplasia while women are taking estrogen. 
None of the studies investigated found that the LNG-IUD was 
superior to other dosage forms, but all did find equal efficacy in 
protecting the uterus from endometrial hyperplasia. The 
possibility of amenorrhea while using LNG-IUD is high, so this is 
a major rationale of using the intrauterine device over oral 
forms of progesterone that may be cyclical. There is a need for 
more research, such as a randomized controlled trial with a 
large sample size and full evaluation of adverse effects to 
conclude the added benefits of LNG-IUD over other dosage 
forms.  
 
Protecting the uterus for women on ERT is essential in 
preventing endometrial hyperplasia. Although it appears that 
LNG-IUD is efficacious in protecting against proliferation of the 
endometrial, it is too soon to definitively conclude that LNG-IUD 
protects against the development of cancer that is linked to 
some forms of endometrial hyperplasia. This systemic review 
did not focus on the development of cancer as it relates to ERT 
and progesterone dosage forms.  
 
Conclusion 
The result of this literature review has found that LNG-IUD is a 
safe dosage form option when combined with ERT and may be 
clinically superior to other progesterone dosage forms (oral, 
vaginal) in regard to side effect profile and additional benefits, 
such as contraception for women in peri-menopause, increased 
compliance, and improved management of bleeding during 
menopause. The selected studies illustrate that LNG-IUD is no 
less effective at suppressing endometrial proliferation when 
compared to other dosage forms, but the studies lack data 
showing superiority. In theory the LNG-IUD should have 
increased benefits due to its minimal systemic exposure, added 
contraception for peri-menopausal women, and ensures 
compliance by delivering a consistent amount of progesterone 
to the body.  More research is needed to firmly confirm this 
conclusion. 
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Figure 1. Flow diagram of literature search and selection criteria adapted from PRISMA.5 
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Table 1. Summary of selected studies’ characteristics and key findings 
Type of study First author 
(year) 
IUD and 
estrogen 
strength 
Comparison No. of subjects Treatment 
period 
Without 
bleeding or 
spotting 
during 
treatment 
LNG-IUD 
group: 
Comparison 
Endometrial 
proliferation 
LNG-IUD 
group: 
comparison 
Discontinued 
therapy 
LNG-IUD group: 
comparison 
Randomized 
control trial  
Andersson 
(1992)9 
20-mcg 
levonorgestrel-
IUD and 2 mg 
oral estradiol 
250 mcg oral 
levonorgestrel 
(cyclic) and 2 mg 
oral estradiol  
40 
(perimenopausal) 
1 year  15/18: 0/19 
after 12 
months 
 
0/18: 0/19 by 
biopsy 
2/20 : 1/20 
Randomized 
control trial  
Raudaskoski 
(1995)10 
20-mcg 
levonorgestrel-
IUD and 50-mcg 
transdermal 
estradiol 
1 mg oral 
norethisterone 
acetate daily and 
2 mg oral 
estradiol  
40 
(postmenopausal) 
1 year 29 days : 29 
days without 
bleeding 
0/15 : 0/17 
by biopsy 
5/20 : 3/20 
Randomized 
control trial 
Antoniou 
(1997)11 
20-mcg 
levonorgestrel-
IUD and 50-mcg 
estradiol 
transdermal 
patch 
100 mg vaginal 
progesterone 
suppository 
(cyclic) and 2 mg 
estradiol vaginal 
ring  
56 
(postmenopausal) 
1 year  31 days : 34 
days without 
bleeding  
0/28 : 0/28 
by 
ultrasound 
0/28 : 0/28  
Randomized 
control trial 
Suvanto-
Luukkonen 
(1998)12 
20-mcg 
levonorgestrel-
IUD and 1.5 mg 
transdermal 
estradiol 
100 mg oral 
natural 
micronized 
progesterone 
capsules OR 200 
mg vaginal 
progesterone 
and 1.5 mg 
transdermal 
estradiol  
51 
(postmenopausal) 
1 year Not reported 0/18 : 0/19 : 
0/15 by 
ultrasound 
0/18 : 0/19 : 0/15 
Randomized 
control trial 
Wollter-
Svensson 
(1997)13 
5-mcg or 10-mcg 
levonorgestrel 
IUD and 50 mcg 
transdermal 
estradiol 
5-mcg or 10-mcg 
levonorgestrel 
IUD and 2 mg 
oral estradiol  
108 
(perimenopausal) 
1 year 59/96 
(groups 
combined) 
amenorrhea 
after 12 
months 
0/45 : 1/51 
(from 
transdermal 
group) by 
ultrasound 
6/51 : 6/57 
Randomized 
control trial 
Raudaskoski 
(2002)14 
20-mcg 
levonorgestrel-
IUD and 2 mg 
oral estradiol 
Medroxyprogest
erone acetate 5 
mg (cyclic) and 2 
mg oral estradiol  
109 
(postmenopausal) 
1 year 54/55 : 0/47 
(bleed 
during week 
off) after 6 
months 
0/55 : 18/47 
by biopsy 
1/56 : 4/53 
Randomized 
control trial 
Boon (2003)15 20-mcg 
levonorgestrel-
IUD and 2 mg 
oral estradiol 
Norethisterone 
and oral 
estradiol (cyclic) 
200 
(perimenopausal) 
26 cycles 29/76 : 0/63 
amenorrhea 
after 12 
months 
0/76 : 0/63 
by biopsy 
24/100 : 37/100 
Non 
comparative, 
prospective 
study 
Wildemeersch 
(2005)16 
14 -mcg 
levonorgestrel 
IUD and 1.5 mg 
oral estradiol 
No comparative 
group 
150 (94 
perimenopausal 
and 56 
postmenopausal) 
1 year Not reported 0 / 101 : N/A 
by biopsy 
8/150 : N/A 
Non-
comparative 
prospective 
study    
Wildemeersch 
(2007)17 
20-mcg 
levonorgestrel-
IUD and 1.5 mg 
oral estradiol 
No comparative 
group   
102 
(postmenopausal) 
5 years  Not reported 0/102 : N/A 
by biopsy 
0/102 : N/A 
Non-
comparative 
prospective 
study 
Hampton 
(2005)18 
20-mcg 
levonorgestrel-
IUD and 1.25 mg 
oral CEE 
No comparative 
group 
82 
(perimenopausal) 
5 years 51/60 
amenorrhea 
after 5 years 
0/60 : N/A by 
biopsy 
22/82 : N/A 
Non-
Comparative 
prospective 
study 
Varila (2001)19 20-mcg 
levonorgestrel-
IUD and 50 mcg 
transdermal 
estradiol or 2 mg 
oral estradiol 
No comparative 
group 
40 
(postmenopausal) 
5 years 25/39 
amenorrhea 
after 1 year 
0/39 after 12 
months and 
0/29 after 5 
years by 
biopsy 
11/40 : N/A 
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Table 2. Methodological appraisal for selected studies using the Critical Appraisal Skills Programme checklist15 
Study 1. Did 
the 
study 
address 
a 
clearly 
focused 
issue? 
2. Was the 
assignment 
of patients 
to 
treatments 
randomized? 
3. Were 
patients, 
health 
workers, 
and study 
personnel 
blinded? 
4. 
Were 
the 
groups 
similar 
at the 
start 
of the 
trial? 
5. Aside from 
experimental 
intervention, 
were the 
groups 
treated 
equally? 
6. Were all 
the 
patients 
who 
entered 
the trial 
properly 
accounted 
for at its 
conclusion? 
7. How 
large 
were the 
treatment 
effects? 
8. How 
precise 
were the 
treatment 
effects? 
9. Can 
the 
results 
be 
applied 
locally? 
10. Were all 
clinically 
important 
outcomes 
considered? 
11. Are 
the 
benefits 
worth 
the 
harms 
and 
costs? 
Associated 
risk of 
potential 
bias 
Andersson 
(1992)9 
Y Y N Y Y Y CT SP Y Y CT Low 
Raudaskoski 
(1995)10 
Y Y N Y Y Y CT SP Y CT CT Low 
Antoniou 
(1997)11 
Y Y N Y Y Y CT P Y CT Y Low 
Suvanto-
Luukkonen 
(1998)12 
Y Y N Y Y Y CT P Y CT CT Low 
Wollter-
Svensson 
(2001)13 
Y Y N Y Y Y CT P Y Y CT Low 
Raudaskoski 
(2002)14 
Y Y N Y Y Y CT SP Y CT CT Low 
Boon  
(2003)15 
Y Y N Y Y Y CT P Y CT CT Low 
Wildemeersch 
(2005)16 
Y N N N/A N/A Y CT NP N CT CT High 
Wildemeersch 
(2007)17 
Y N N N/A N/A Y CT NP N CT CT High 
Hampton 
(2005)18 
Y N N N/A N/A Y CT P Y Y CT High 
Varila  
(2001)19 
Y N N Y N/A Y CT SP CT Y CT Moderate 
Abbreviations: Y=Yes; N=No; CT=Couldn’t Tell; P=Precise; SP=Somewhat Precise; NP=Not Precise. 
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Table 3. Cochrane Risk of Bias Tool16 
Article Selection Bias Performance 
Bias 
Detection 
Bias 
Attrition 
Bias 
Reporting 
Bias 
Other Bias Total 
Random 
Sequence 
Generation 
Allocation 
Concealment 
Blinding of 
Participants 
and 
Personnel 
Blinding of 
Outcome 
Assessment 
Incomplete 
Outcome 
Data 
Selective 
Reporting 
Anything 
Else, Ideally 
Prespecified 
Low on 
Risk of 
Bias 
Andersson (1992)9 Low Unclear High High Low Low Low 5/7 
Raudaskoski (1995)10 Low Low High Low Low Low Low 6/7 
Antoniou (1997)11 Low Unclear High Low Low Low Low 6/7 
Suvanto-Luukkonen (1998)12 High Unclear High Low Low Low Low 5/7 
Wollter-Svensson (2001)13 Low Low High Low Low Low Low 6/7 
Raudaskoski (2002)14 Low Low Low Unclear High Low Low 6/7 
Boon (2003)15 Low Low Low Low Unclear Low Low 7/7 
Wildemeersch (2005)16 High High High High Low Low High 2/7 
Wildemeersch (2007)17 High High High High Low Low High 2/7 
Hampton (2005)18 High High High High Low Low Low 3/7 
Varila (2001)19 High High High High Low Low Low 3/7 
 
 
 
 
 
 
 
 
 
Appendix A:  Search Strategies 
Database Search 
OVID MEDLINE (April 16, 2018) 
 
1. Levonorgestrel/ OR Levonorgestrel.it,ab. OR LNG.ti,ab.;  
2. Exp Intrauterine Devices/ OR intrauterine device*.ti,ab. OR intrauterine system*.ti,ab.;  
3. Exp Hormone Replacement Therapy/ OR “Hormone Replacement Therapy”.ti,ab. OR 
“estrogen replacement therapy”.ti,ab. OREstradiol.ti,ab. OR exp Estradiol;  
4. Endometrial.ti,ab. OR exp Endometrium/ OR exp Endometrial Neoplasms/ OR 
Endometrial Hyperplasia/;  
Combination of:  #1 and #2 and #3 and #4 
COCHRANE (June 9, 2019) 
 
1. Levonorgestrel.;  
2. Intrauterine Devices;  
3. Hormone Replacement Therapy;  
4. Endometrial;  
Combination of:  #1 and #2 and #3 and #4 
SCOPUS (June 16, 2019) 1. Levonorgestrel 
2. Intrauterine Devices 
3. Hormone Replacement Therapy OR Estrogen Replacement Therapy 
4. Endometrial 
Combination of: #1 and #2 and #3 and #4 
 
 
